Literature DB >> 14648656

The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix.

G Denise Zielinski1, Peter J F Snijders, Lawrence Rozendaal, Nathalie Fransen Daalmeijer, Elle K J Risse, Feja J Voorhorst, N Medi Jiwa, Hans C van der Linden, Frits A de Schipper, Arnold P Runsink, Chris J L M Meijer.   

Abstract

Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population-based screening programmes. Adding high-risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix. Archival formalin-fixed specimens of indisputable ACIS (n=65) and AdCA (n=77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR-enzyme immunoassay (EIA) and type-specific E7 PCR for 14 hrHPV types. Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV-positive. HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs. Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV-positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p<0.001). Immunostaining for p53, pointing to stabilized wild-type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p=0.01). No difference in p16INK4a and p53 immunostaining was found between hrHPV-negative cervical AdCAs and endometrial AdCAs. Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV. Since all ACISs and nearly all cervical AdCAs were hrHPV-positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648656     DOI: 10.1002/path.1480

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

1.  Prospective study of human papillomavirus and risk of cervical adenocarcinoma.

Authors:  Lisen Arnheim Dahlström; Nathalie Ylitalo; Karin Sundström; Juni Palmgren; Alexander Ploner; Sandra Eloranta; Carani B Sanjeevi; Sonia Andersson; Thomas Rohan; Joakim Dillner; Hans-Olov Adami; Pär Sparén
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

2.  Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis.

Authors:  Lea A Moukarzel; Ana M Angarita; Christopher VandenBussche; Anne Rositch; Carol B Thompson; Amanda N Fader; Kimberly Levinson
Journal:  J Low Genit Tract Dis       Date:  2017-04       Impact factor: 1.925

Review 3.  Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfalls.

Authors:  David C Wilbur
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

4.  Emerging relationships between papillary proliferation of the endometrium and endometrial carcinoma: evidence from an immunohistochemical and molecular analysis.

Authors:  Qin Liu; Qiongyan Wu; Minghua Yu; Haiyan Shi; Bingjian Lu
Journal:  Virchows Arch       Date:  2019-05-12       Impact factor: 4.064

5.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

6.  Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma.

Authors:  Li Gong; Wen-Dong Zhang; Xiao-Yan Liu; Xiu-Juan Han; Li Yao; Shao-Jun Zhu; Miao Lan; Yan-Hong Li; Wei Zhang
Journal:  Diagn Pathol       Date:  2010-04-24       Impact factor: 2.644

7.  Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women.

Authors:  Carolina Porras; Ana Cecilia Rodríguez; Allan Hildesheim; Rolando Herrero; Paula González; Sholom Wacholder; Robert D Burk; Mark Schiffman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03       Impact factor: 4.254

8.  Relationship among human papillomavirus infection, p16(INK4a), p53 and NF-κB activation in penile cancer from northern Thailand.

Authors:  Masachika Senba; Naoki Mori; Shuichi Fujita; Prapan Jutavijittum; Amnat Yousukh; Kan Toriyama; Akihiro Wada
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

9.  p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma.

Authors:  Nabiha Missaoui; Sihem Hmissa; Lucien Frappart; Amel Trabelsi; Atef Ben Abdelkader; Cheick Traore; Moncef Mokni; Mohamed Tahar Yaacoubi; Sadok Korbi
Journal:  Virchows Arch       Date:  2006-02-22       Impact factor: 4.064

Review 10.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

Authors:  I Tsoumpou; M Arbyn; M Kyrgiou; N Wentzensen; G Koliopoulos; P Martin-Hirsch; V Malamou-Mitsi; E Paraskevaidis
Journal:  Cancer Treat Rev       Date:  2009-03-03       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.